No patient left behind: The promise of immune priming with epigenetic agents

No patient left behind: The promise of immune priming with epigenetic agents

Checkpoint inhibitors, monoclonal antibodies that inhibit PD-1 or CTLA-4, have revolutionized the treatment of multiple cancers. Despite the enthusiasm for the clinical successes of checkpoint inhibitors, and immunotherapy, in general, only a minority of patients with specific tumor types actually b...

Full description

Bibliographic Details
Main Authors: Corey A. Carter, Bryan T. Oronsky, Joseph Roswarski, Arnold L. Oronsky, Neil Oronsky, Jan Scicinski, Harry Lybeck, Michelle M. Kim, Michelle Lybeck, Tony R. Reid
Format: Article
Language:English
Published: Taylor & Francis Group 2017-10-01
Series:OncoImmunology
Subjects:
immunotherapy
immunosuppression
immunogenic cell death
epigenetic modulation
checkpoint inhibitors
resistance
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1315486

Internet

http://dx.doi.org/10.1080/2162402X.2017.1315486

Similar Items